Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial

Gourgou-Bourgade, S.; Mollévi, Caroline; Desseigne, Françoise; Ychou, Marc; Bouché, Olivier; Guimbaud, Rosine; Bécouarn, Y.; Adenis, Antoine; Raoul, Jean‐Luc; Boige, Valérie; Bérille, J.; Conroy, Thierry

doi:10.1200/jco.2012.44.4869

Public

Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial

Published in Journal of Clinical Oncology • Dec 4, 2012

Authors:

S. Gourgou-Bourgade

Caroline Mollévi

Françoise Desseigne

Abstract

PURPOSE: To compare the quality of life (QoL) of patients receiving oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) or gemcitabine as first-line chemotherapy and to assess whether pretreatment QoL predicts survival in patients with metastatic pancreatic cancer. PATIENTS AND METHOD...

Subject

Medicine

FOLFIRINOX

Oxaliplatin

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!